

INVESTOR PRESENTATION

January 18, 2024



ADVANCING CHEMISTRY. ENHANCING HEALTH



FORWARD LOOKING STATEMENTS

Sirona Biochem cautions you that statements included in this presentation that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.





TABLE OF CONTENTS

Investment Highlights
Share Information
Business Model Strategy
Product Pipeline
Worldwide IP Portfolio
Milestones
GlycoProteMim™
The Science
Studies and Results
Advantage

•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	4
•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	5
•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	6
•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	7
•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	10
•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	11
•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	12
•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	13
•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	14
•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	16



Sirona Laboratories™ Global Launch Plan Projected Sales and Revenue Anticipated Product Line Facilities/M. Partners Technology Management Contact Us Sources

•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	18
•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	20
•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	21
•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	22
•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	23
•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	24
•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	27
•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	29
•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	30



INVESTMENT HIGHLIGHTS

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Through its wholly-owned French subsidiary TFChem, the Company specializes in stabilizing carbohydrate molecules to improve efficacy and safety. Sirona Biochem's business model is to develop active ingredients for commercialization or for licensing out for upfront payments, milestones, and royalties.

- States Trademark and Patent Office
- products with AbbVie.
- **Disruptive** proprietary carbohydrate-bonding platform based on 20 years of research and development.
- Strong worldwide IP portfolio, including North America, European Union, and Asia.
- **Pharmaceutical** Developing Anti-viral TBD compound for \$36B USD anti-viral market.^[9]
- State-of-the-art, multi-million dollar laboratory in France with top scientific team, strong global manufacturing partner (Wuxi AppTec, China).



Signed global exclusive licensing deal with Allergan Aesthetics, an AbbVie [NYSE: ABBV] company, for TFC-1067 and library of cosmetic compounds.^[3] Applied for an international trademark for TFC-1326, as GlycoProteMim[™], with the Instituto Nacional da Propriedade Industrial (INPI) and the United

Ongoing royalty payments on net sales generated by AbbVie product line based on licensed patented ingredients. Potential to cooperate on additional

Cosmetics - Developing disruptive solutions for anti-aging (\$12.5B USD)^[5], cell preservation (\$7.5B USD)^[7], and cellulite treatment (\$1.4B USD)^[8].



SHARE INFORMATION



Shares owned by Insiders: 15%

Sirona Biochem is a publicly listed company traded on the TSX Venture (TSX-V: SBM), Börse Frankfurt (FSE: ZSB), and OTC (OTC: SRBCF)

FRANKFURT

BÖRSE

TSX-V: SBM | FSE: ZSB | OTC: SRBCF

тsx venture

EXCHANGE




FRANKFURT STOCK ZSB

EUR€0.082


FUNDAMENTAL DATA	(CAD)
TSX-V	SBM
Shares Outstanding	253,604,505
Shares Fully Diluted	275,429,505
Share Price (CAD)	\$0.12
Market Cap	\$30,432,541
Year High	\$0.215
Year Low	\$0.065

*January 18, 2024
















BUSINESS MODEL & STRATEGY

Sirona Biochem's strategy is to commercialize, license, or sell patented compounds to leading global companies in return for up-front fees, milestone fees and ongoing royalty payments.





PRODUCT PIPELINE



Pharmaceutical Products



Sirona Biochem has invested extensively in developing its products to meet the need of patients and industry partners. The compounds created through our **proprietary platform** go through rigorous tests and regulatory scrutiny to verify their safety and efficacy.









COSMETIC PRODUCTS

Therapeutic Area	Compound	
Skincare - Dark spot corrector (Rx & OTC)	TFC-1067 & family of dark spot correctors	• Exclusive
Cell Preservation & Repair (incl keloid & scar therapy)	Glycoprotein Library	• In vitro tes
Skincare - Anti-Aging/ Anti-wrinkle	GlycoProteMim™ (TFC-1326)	CompletedIn discussionTrademark
Skincare - Cellulite Treatment	TBA	• Ongoing re

ESTIMATED MARKET SIZE

Skincare - Anti-Aging/Anti-wrinkle	\$12.5
Skincare - Dark spot corrector (Rx & OTC)	\$8B U
Cell Preservation & Repair (incl keloid & scar therapy)	\$7 . 5B
Skincare - Cellulite Treatment	\$1.45



Status

licensing deal with AbbVie for TFC-1067 signed [3]

sting for lead determination

ed safety studies - awaiting dose approval and batch manufacturing for clinical trial ^[4] sion for R&D partnership

king of GlycoProteMim™ name

research & development




B USD 🗁

5B USD ^[8]



PHARMACEUTICAL PRODUCTS



Sirona Biochem is continually discovering new compounds and molecules with the goal of advancing global health and skin care.

TSX-V: SBM | FSE: ZSB | OTC: SRBCF



Status





WORLDWIDE IP PORTFOLIO

Sirona Biochem has a strong IP portfolio, including a recently filed patent for its breakthrough anti-aging compound GlycoProteMim[™] (TFC-1326), managed by intellectual property law firm Cabinet Regimbeau [11]

LUIIVIDLAU Creative IP





MILESTONES

Milestones achieved in the last 18 months:

✓ Completed an exclusive, global license with AbbVie for TFC-1067 \checkmark Completed the terms of manufacturing and supply of TFC-1067 for AbbVie \checkmark Published research in the renowned Journal of Cosmetic Dermatology ^[13] \checkmark Reached first product commercialization with TFC-1067 ^[2] \checkmark Discovered potential anti-cellulite activity in compounds ✓ Successfully completed clinical trial for anti-aging GlycoProteMim^{™[14]} \checkmark Signed agreement with Pullan Consulting for negotiation and strategy on TFC-1067 151 V Developed a library of 20 novel antiviral compounds and completed initial screening for for library and completed initial screening for covid activity \checkmark Completed a significant patent extension for the anti-aging compounds ✓ Initiated launch of Sirona Laboratories – for commercialization of GlycoProteMim™

Sirona is working intensively towards achieving the following milestones:

- Advance and patent the SGLT2 inhibitor in third therapy area
- Commercialize GlycoProteMim within newly formed subsidiary Sirona Laboratories
- Secure non-dilutive funding through grants
- File patents around novel compounds and therapy areas of interest
- Further R&D studies on library of Anti-Viral Compounds
- Continue to advance novel Cosmetic Ingredients in the areas of Cellulite and Wound-Care

*The milestones listed are not in chronological order. The achievement of milestones is mostly dependent on external partners and factors over which we have limited control. Accordingly, we will no longer provide a precise time estimate. We will immediately update shareholders on material items as they arise.





GlycoProteMim[™] **TFC-1326**

REDEFINING ANTI-AGING SCIENCE

GlycoProteMim™ (TFC-1326) represents a paradigm shift in the world of anti-aging skincare.

Inspired by nature's own protective mechanisms, GlycoProteMim™ is poised to revolutionize the US\$12.5 billion anti-aging and anti-wrinkle market.^[5]

https://www.glycoprotemim.com


Our cutting-edge active ingredient is the culmination of over **US\$15 million** in research and development spanning 23 years.



TFC-1326 (GlycoProteMim[™]): The Science

Novel Non-invasive Anti-Aging Anti-Wrinkle Technology

GlycoProteMim[™] is based on the **naturally occurring glycoproteins** found in Antarctic fish, known to protect them against environmental stressors. **Dr. Géraldine Deliencourt-Godefroy developed and perfected GlycoProteMim[™] (TFC-1326)** over a span of 23 years. Now, it is a clinically proven breakthrough compound, effective at reversing skin aging.



Aging reduces collagen and elastin production. Fibroblast activity declines resulting in **decreased elasticity and firmness**. The epidermal layer thins, **weakening the skin's protective barrier** and making it more susceptible to damage.



GlycoProteMim[™] heightens cellular response to reactive oxygen species (ROS) and boosts SOD2. The compound also enhances hyaluronic acid synthesis and increases fibroblast proliferation, fortifying the collagen I network.



TFC-1326 (ClycoProteMimTM): Studies and Results

Clinical Trial for GlycoProteMim[™] in Paris


The clinical trial was designed to assess the compound's efficacy in reversing aging facial skin, including restoring lost volume (plumping) and reducing fine wrinkles. The formulation was a cream base with GlycoProteMim[™] TFC-1326 at a concentration of 1%. The formution included no other active ingredient. The cream was applied twice daily for 12 weeks.

The following results were achieved:

- **37%** Increased Skin Density (Collagen and Elastin)
- **54%** Decreased inflammation
- 12% reduction in the depth of crow's feet wrinkles
- **75%** of participants reported a visible reduction in wrinkles
- Remodeled the oval of the face


*Additional results are provided in our trial results news release and on our website.







Results of using GlycoProteMim[™] after 12 Weeks



*Unretouched photos, taken in standard lighting. **Results may vary**

To best understand its numerous benefits and safety profile, extensive testing on the cellular level has also occurred in multiple research facilities. TFC-1326 has many properties **superior to the "gold standard"** retinoid based anti-aging products.





Visible wrinkle reduction

Improved skin quality and density

Face reshaped due to tighter skin

Reduced inflammation





TFC-1326 (GlycoProteMimTM): Advantage

GlycoProteMim™ stands out as a beacon of innovation and safety. Unlike traditional alternatives such as toxins, dermal fillers, and retinoids, GlycoProteMim™ offers a unique solution that is safe and effective in reversing skin aging.

GlycoProteMim[™] TFC-1326

Safety for All Skin Types

GlycoProteMim[™] is designed for all skin types. In stark contrast, alternatives such as retinoids, toxins, and dermal fillers, although considered safe, come with a list of potential adverse effects.

Anti-Aging Efficacy

Our patented compound not only boasts powerful anti-inflammatory effects but also reverses aging and repairs skin, offering a comprehensive and permanent solution. In contrast, alternatives only provide limited antiaging benefits without reparative properties.



Natural Progression, Not Injection

GlycoProteMim[™] is a topical application, avoiding the need for invasive injections. Unlike toxins and dermal fillers, which involve injection procedures, GlycoProteMim[™] ensures a convenient and user-friendly experience without compromising on effectiveness.

Multifaceted Benefits:

From improving skin laxity and quality to providing UV protection and enhancing the skin barrier, GlycoProteMim[™] outshines alternatives.
Retinoids, while effective, come with challenges like skin irritation and a lengthy onset period, making GlycoProteMim[™] a more versatile and user-friendly choice.



GlycoProteMim[™] vs other anti-aging Compounds: Table

	GlycoProteMim (TFC - 1326)	Toxins	Dermal Fillers	Retinoids
	Unique patented Compound owned by Sirona Biochem	Botox®, Dysport®, Xeomin®, Jeuveau™	Juvéderm®, Multiple others	Tretinoin, Retinaldehyde, Retinol, Retinal, Retinyl acetate, Retinyl propionate, Retinyl palmitate
Application	Topical	Injection	Injection	ТорісаІ
Time to onset	8 weeks then progressive improvement	3-5 days	Immediate	Up to 6 months
For Sensitive Skin	Safe	Safe	Safe	Avoid Use
Adverse Effects	None to date	Yes, long list of side effects	Yes, long list of side effects	Yes, irritant reaction in 10%
Anti-inflammatory Effect	Powerful	None	None	Mixed Effect
Anti-Aging Effect	Reverses Aging / Repairs	None	None	Forces skin reproduction
Antioxidant	Yes	No	No	Yes
Anti-Wrinkle	Yes	Yes	Yes	Yes, with Prescription Strength
Improve Skin Laxity	Yes	No	Yes	No
Improve Skin Quality	Yes	No	No	Yes, but limited
Face Shape Remodeling	Yes	No	Yes	No
UV Protection	Yes	No	Νο	No, avoid UV light
Improve Skin Barrier	Yes	No	Νο	No, damages skin barrier
Cruelty-Free	Yes	No	Νο	No

GlycoProteMim[™] presents a groundbreaking alternative to the current "gold standard" retinoid-based treatments. Unlike retinoids, which compromise the skin's barrier and lead to side effects such as flaking, peeling, redness, irritation, and increased sensitivity, GlycoProteMim[™] enhances the skin barrier and repairs the skin from the inside out without any adverse effects.

GlycoProteMim™ is not just a product but a paradigm shift in anti-aging skincare.







Introducing **Sirona Laboratories™**, our new wholly-owned cosmetics subsidiary. Established with a vision to maximize the commercial potential of our breakthrough anti-aging skincare ingredient, **GlycoProteMim™**. Sirona Laboratories represents a strategic leap into the aesthetics market and the future of skincare.

In our pursuit to redefine the anti-aging skincare market, we chose to create Sirona Laboratories[™] as a distinct entity. This decision was prompted by GlycoProteMim[™]'s **amazing clinical trial results** and our commitment to setting a new benchmark in the industry.



SITONA laboratoriesTM

powered by

GlycoProteMim[™] TFC-1326






Changing the Game

Through **Sirona Laboratories™**, we are aiming to achieve several ambitious goals. Our primary objectives include establishing GlycoProteMim[™] as the **new "Gold Standard" in anti-aging skincare** ingredients, while also setting new standards in effectiveness and safety.


To realize these goals, we're strategically collaborating with industry experts to harness our clinically proven science. These efforts are not just about commercial success; they are about creating sustainable value for our shareholders and the entire skincare industry.







PROJECTED SALES AND REVENUE







ANTICIPATED PRODUCT LINE

Anti-Aging Series

- Anti-Aging Serum Ampoules
- (0.5%) Anti-Aging Cream
- (0.2%) Mild Anti-Aging Cream

Therapeutic Series

- Anti-Cellulite Cream
- Hand Cream


ANTI-AGING SERUM

Intensive 21-Day Therapy











FACILITIES/MANUFACTURING PARTNER

Sirona Biochem Laboratory

TFChem Laboratory, France

The 502-square-meter laboratory is located in Val de Reuil, France. This state-of-the-art facility is located in France's Cosmetic Valley, wheretheworld'sleadingcosmeticcompanies conduct their research and development.

Theaward-winningteamworkingatthefacility specializes in developing fluorinated building blocks, which addresses the limitations usually associated with the application of carbohydrate-based molecules as active ingredients.

www.sironabiochem.com

Manufacturing Partner - TFC-1067

WuXi AppTec, China

WuXi AppTec provides a broad R&D and manufacturing services portfolio that enables the global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients.

The company has research, development, and manufacturing facilities in China, South Korea, the U.S., Germany, the UK, Switzerland, and Israel.

www.wuxiapptec.com

TSX-V: SBM | FSE: ZSB | OTC: SRBCF



Anti-aging: GlycoProteMim™ Laboratory

DIVA Laboratory, France

We're currently working with DIVA on anti-aging.

www.diva-expertise.com









TECHNOLOGY

Our world-class team is comprised of award-winning scientists who have worked for Fortune 500 companies such as Sanofi, GSK and Bayer.







Geraldine Deliencourt-Godefroy, PhD

D'III &

Founder, TFChem Chief Scientific Officer Our Technology has received more than **\$8M CAD** in grants from the French Government, including new financing to develop its advance chemistry process.



Carbohydrate compounds have immense commercial potential.

• They are involved in many of our body's biological processes and are also used for development of active ingredients in pharmaceuticals and cosmetics

Examples of successful carbohydrate-based drugs are:

- Anti-viral medications such as **Tamiflu**, used for the treatment of Influenza A
 - Tamiflu: sales passed \$931 Million USD during swine flu epidemic (2019) [24]
- Blood thinners, such as: Arixtra and Lovenox, for the treatment of blood clots
 - Lovenox: sales of \$1.46 Billion USD (2018) [25]



The challenges with carbohydrates are:

- Carbohydrates have complex syntheses requiring expert chemists
- Carbohydrates are unstable, causing lower efficacy or toxic by-products
- Carbohydrates have poor pharmacological properties


Sirona Biochem's proprietary chemistry increases the potential and reduces the drawbacks

of carbohydrate molecules



- Sirona's Fluorination Chemistry Technology is **the solution** to **unstable carbohydrate molecules**.

- The chemistry strengthens the bonds of a carbohydrate molecule by strategically placing fluorine atoms.





MANAGEMENT



Howard J. Verrico, MD

Founder, Sirona Biochem CEO and Chairman of the Board



Geraldine Deliencourt-Godefroy, PhD

Founder, TFChem Chief Scientific Officer Dr. Verrico obtained his medical degree from the University of Toronto in 1985 and has been a member of the College of Physicians and Surgeons of British Columbia since July 1986. Dr. Verrico has extensive experience as a venture capitalist in the junior capital markets. He has acted as a venture capitalist for over 30 years, funding numerous start-ups and early-stage companies both in the private and public marketplace. He is the original founder of Sirona Biochem building the company by investing his personal funds starting in 2006, He has accumulated his large share position through personal share purchases. He currently is solely focused on the success and growth of SIRONA Biochem as it enters a stage of rapid growth.

Dr. Géraldine Deliencourt-Godefroy is an award-winning synthetic chemist and the founder of Frenchbased biotechnology company TFChem. Since the acquisition of TFChem by Sirona Biochem in March 2011, Dr. Deliencourt-Godefroy has assumed the role of Chief Scientific Officer. Her scientific research in carbohydrate chemistry has led to the discovery of new drug families and the development of drug candidates for diabetes and obesity, cosmetic ingredients and biological adjuvants. Previous to founding TFChem, Dr. Deliencourt-Godefroy was a scientific leader at INSA (National Institute of Applied Sciences) in Rouen, France, where she developed a new technology for stabilized carbohydrates. Previous roles also include a post-doctoral position at the University College London and doctoral research at the Research Institute of Fine Organic Chemistry in Rouen, France. Dr. Deliencourt-Godefroy received a PhD and Masters in Organic Chemistry as well as her business degree from the University of France. She is the author of several publications and patents and is also the recipient of the acclaimed Francinov Research and Innovation Medal, French Ministry of Research Award and the French Senate Award.









Christopher Hopton, CPA, CGA

Chief Financial Officer

Christopher Hopton, Sirona Biochem's Chief Financial Officer, brings 28 years of expertise in financial management and operations. His extensive experience covers areas of financial planning, accounting policy and business process improvement. As a business investment and finance consultant, Mr. Hopton has worked with several public and privately-held companies. Most recently, Mr. Hopton was the Chief Financial Officer of Central Resources Corp., a junior mineral exploration company. Formerly, he held the position of Division Controller at Canadian Airlines where he was responsible for an annual operating budget of \$200M. Mr. Hopton was also involved in the restructuring of 360 Networks, a network communications company, which led to a buyout by Bell Canada. Mr. Hopton earned his Bachelor of Business Administration from Simon Fraser University in British Columbia, Canada and received his professional designation as a Certified General Accountant.







CONTACT US

Sirona Biochem: Corporate Office Parent Company - founded 2009



Sirona Biochem Corp. c/o WeWork 595 Burrard Street, Vancouver, BC V7X 1L4

PHONE: +1.604.641.4466 **EMAIL:** info@sironabiochem.com **WEBSITE:** www.sironabiochem.com



TFChem: Laboratory Wholly Owned Subsidiary - acquired in 2011



TFChem Voie de l'innovation Pharma Parc II 27100 Val de Reuil France

PHONE: +33(0)2.32.09.01.16 *FAX:* +33(0)2.32.25.07.64 **EMAIL:** contact@tfchemistry.com



SOURCES

- https://onlinelibrary.wiley.com/doi/10.1111/jocd.13771
- https://www.rodanandfields.cotm/en-us/shop/targeted-dark-spot-corrector/p/RVST015 2.
- https://www.globenewswire.com/news-release/2022/06/13/2461193/0/en/Sirona-Biochem-Announces-Exclusive-Global-Licensing-Agreement-with-Allergan-Aesthetics.html 3.
- https://www.biospace.com/article/releases/sirona-biochem-reports-positive-results-in-safety-study-for-anti-aging-compound-tfc-1326/ 4.
- https://www.factmr.com/report/4337/anti-aging-and-anti-wrinkle-products-market 5.
- https://www.grandviewresearch.com/industry-analysis/skin-lightening-products-market 6.
- https://www.grandviewresearch.com/industry-analysis/cellulite-treatment-market 8.
- https://www.reportsanddata.com/press-release/global-antiviral-drugs-market
- https://www.mordorintelligence.com/industry-reports/sglt-2-market 10.
- https://www.sironabiochem.com/sirona-biochem-adds-french-patenting-top-gun-lawyer-to-its-scientific-advisory-board/
- https://www.newswire.ca/news-releases/sirona-biochem-reports-excellent-results-in-new-clinical-study-on-tfc-1067-881933919.html 12.
- https://markets.businessinsider.com/news/stocks/sirona-biochem-announces-acceptance-of-clinical-study-for-tfc-1067-in-the-journal-of-cosmetic-dermatology-1029718558
- https://www.globenewswire.com/news-release/2014/09/22/1343131/0/en/Sirona-Biochem-Launches-Anti-Aging-Preclinical-Studies.html 14.
- https://www.newswire.ca/news-releases/sirona-biochem-announces-engagement-of-pullan-consulting-to-close-optimal-deal-for-tfc-1067-803127057.html 15.
- https://www.bloomberg.com/press-releases/2020-03-31/-r-e-p-e-a-t-sirona-biochem-initiates-covid-19-and-infectious-diseases-development-program 16.
- https://www.gminsights.com/industry-analysis/animal-healthcare-market
- https://vetsource.com/news/pet-diabetes-facts/ 18.
- https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2021-financial-results/
- https://www.boehringer-ingelheim.com/media-overview/press-releases/boehringer-ingelheim-good-2021-business-performance
- https://investor.zoetis.com/news/news-details/2022/Zoetis-Reports-Fourth-Quarter-and-Full-Year-2021-Results/default.aspx
- https://covetrus.com/covetrus-announces-financial-results-for-fourth-quarter-and-full-year-of-2021/
- https://investor.elanco.com/press-releases/press-releases-details/2022/Elanco-Animal-Health-Reports-Fourth-Quarter-and-Full-Year-2021-Results/default.aspx
- 24. https://www.nytimes.com/2009/07/24/business/24roche.html
- 25. https://www.sanofi.com/-/media/Project/One-Sanofi-Web/Websites/Global/Sanofi-COM/Home/en/investors/docs/press-releases/Q42018results.pdf



https://www.globenewswire.com/news-release/2021/09/22/2301486/0/en/Cell-and-Tissue-Preservation-Market-to-Surpass-US-8-5-Billion-by-2028-CAGR-11-5-Says-Acumen-Expert.html





SICON BIOCHEM

TSX-V: SBM FSE: ZSB | OTC: SRBCF

